Literature DB >> 9354415

Proarrhythmia with class III antiarrhythmic drugs: types, risks, and management.

S H Hohnloser1.   

Abstract

The nature of the proarrhythmic reactions induced by antiarrhythmic drugs is linked to the electrophysiologic effects of these agents. Torsades de pointes is the classic form of proarrhythmia observed during therapy with any drug that prolongs repolarization, for example, the class III agents. Its precise electrophysiologic mechanism is not fully elucidated, although the arrhythmia is generally considered to be due either to early afterdepolarization in the context of prolonged cardiac repolarization or to an increase in spatial or temporal dispersion of repolarization. Among the class III drugs the proarrhythmic risk appears to be lowest for amiodarone, probably due to its complex electrophysiologic profile that may create significant myocardial electrical homogeneity. In the case of d,l-sotalol, the incidence of torsades de pointes increases with dose and the baseline values of the QT interval. Where d-sotalol and other pure class III agents might fall into the varying spectrum of proarrhythmic potential remains unclear. That d-sotalol has been found to increase mortality in postinfarction patients with ventricular dysfunction (the Survival With Oral d-Sotalol [SWORD] trial) is a matter of considerable concern. It raises the possibility that such a phenomenon may be a common property of most, if not all, pure class III compounds. Accordingly, care must be taken to minimize the likelihood of proarrhythmia; in particular, therapy with a class III agent should only be initiated in the presence of a defined indication established on the basis of clinical trials. When class III antiarrhythmic drug-induced proarrhythmia occurs, immediate cessation of therapy with the responsible agent and correction of predisposing factors, such as electrolyte disorders or bradycardia, is mandatory. Intravenous administration of high-dose magnesium sulfate has been demonstrated to be effective in terminating and preventing new episodes of torsades de pointes. Temporary pacing may be necessary.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9354415     DOI: 10.1016/s0002-9149(97)00717-0

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  20 in total

1.  Weighing the QT intervals with the slope or the amplitude of the T wave.

Authors:  Kaspar Lund; Hans Nygaard; Anders Kirstein Pedersen
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-01       Impact factor: 1.468

2.  Comparison of electrophysiological and antiarrhythmic effects of vernakalant, ranolazine, and sotalol in canine pulmonary vein sleeve preparations.

Authors:  Serge Sicouri; Marc Pourrier; John K Gibson; Joseph J Lynch; Charles Antzelevitch
Journal:  Heart Rhythm       Date:  2011-10-20       Impact factor: 6.343

Review 3.  Gene therapies for arrhythmias in heart failure.

Authors:  Fadi G Akar; Roger J Hajjar
Journal:  Pflugers Arch       Date:  2014-02-26       Impact factor: 3.657

4.  The prognostic accuracy of different QT interval measures.

Authors:  Kaspar Lund; Juha S Perkiömäki; Christian Brohet; Hanne Elming; Mohammed Zaïdi; Christian Torp-Pedersen; Heikki V Huikuri; Hans Nygaard; Anders Kirstein Pedersen
Journal:  Ann Noninvasive Electrocardiol       Date:  2002-01       Impact factor: 1.468

Review 5.  Evaluation of drug-induced QT interval prolongation: implications for drug approval and labelling.

Authors:  M Malik; A J Camm
Journal:  Drug Saf       Date:  2001       Impact factor: 5.606

6.  A comparison of the QT and QTc dispersion among patients with sustained ventricular tachyarrhythmias and different etiologies of heart disease.

Authors:  J Kluger; D Giedrimiene; C M White; J Verroneau; E Giedrimas
Journal:  Ann Noninvasive Electrocardiol       Date:  2001-10       Impact factor: 1.468

Review 7.  Pharmacogenetic issues in thorough QT trials.

Authors:  Richard S Judson; Benjamin A Salisbury; Carol R Reed; Michael J Ackerman
Journal:  Mol Diagn Ther       Date:  2006       Impact factor: 4.074

8.  Effect of selection of QTc formula on eligibility of cancer patients for phase I clinical trials.

Authors:  Mitesh J Borad; Arundhati D Soman; Martin Benjamin; Daniel Casa; Waibhav D Tembe; Barbara F Piper; Ramesh Ramanathan; Raoul Tibes; Gayle Jameson; Karen Ansaldo; Daniel D Von Hoff
Journal:  Invest New Drugs       Date:  2012-12-16       Impact factor: 3.850

Review 9.  Antipsychotic-related QTc prolongation, torsade de pointes and sudden death.

Authors:  Peter M Haddad; Ian M Anderson
Journal:  Drugs       Date:  2002       Impact factor: 9.546

Review 10.  QT prolongation with antimicrobial agents: understanding the significance.

Authors:  Robert C Owens
Journal:  Drugs       Date:  2004       Impact factor: 9.546

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.